Although our formula will be a brand-new material for orthopedics, it’s important to note that magnesium cardiac stents have been in use for some time, with good results.
Our alloy will be unique in that it seeks to supply the rigid structure needed for orthopedic indications, which led us to create a different formulation than what is used for cardiac applications.
However, the success of the cardiac magnesium implants gives us confidence in the potential our alloy has for orthopedic applications.
The hardware used for many indications, such as foot and ankle surgeries, needs to be made from metal for strength and stability. Yet many patients experience pain from the hardware until the surgeon goes back and does a second surgery to remove the hardware once they are healed. In the meantime, they have to live with the pain.
This second surgery is often more invasive than the first surgery because of the likelihood of scar tissue and bone adhesion.
The hardware made from our alloy will be strong enough to allow the bone to heal, while slowly absorbing into the body thus eliminating hardware pain and the need for a second surgery.
We’re about three years into our development cycle. We’ve done a significant amount of testing in small and large animals to understand the material and we’ve been able to demonstrate efficacy in a long-term animal model in a bone-to-bone fusion indication.
We are currently in discussion with regulatory agencies both in the US and overseas about the ability to perform initial safety studies for the material in humans. We’re also looking at additional developments that are more complex. Those initial devices will specifically look at soft tissue repair of the shoulders, which is of particular interest to us.
Magnesium can play a number of interesting roles and now that we’ve started down the road of thinking in terms of a metal that resorbs, a whole new world of applications has been opened to us. We believe this new material will afford us astounding opportunities to solve problems in ways they’ve never been solved before.
HOLLAND, Mich., March 11, 2019 /PRNewswire/ — Genesis Innovation Group’s cultivate(MD) Capital Fund II, LP, a fund focused on investments into early stage healthcare companies with innovative technologies, announces its …
Holland, MI-based medical device startup Magnesium Development Company (MDC) announced earlier this month that it has raised a $1 million seed round. Start Garden’s venture fund and Genesis Innovation Group …
